Roche Says No Safety Issues With Halozyme-Partnered Drug

Sources at Roche (OTCQX: RHHBY) told PropThink on Wednesday that products being jointly developed with Halozyme Therapeutics (NASDAQ: HALO) will not face issues seen with HyQ, an intravenous immunoglobulin (IVIg) candidate being jointly developed with Baxter International (NYSE: BAX), or ViroPharma’s (NASDAQ: VPHM) Halozyme-enhanced formulation of Cinryze.